首页> 外文期刊>癌症生物学与医学:英文版 >Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer
【24h】

Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer

机译:具有晚期非小细胞肺癌的长期幸存者的临床病理和分子特征

获取原文
获取原文并翻译 | 示例
       

摘要

Objective:Long-term survivors(LS)of non-small cell lung cancer(NSCLC)without driver alterations,displaying an overall survival(OS)of more than 3 years,comprise around 10%of cases in several series treated with chemotherapy.There are classical prognosis factors for these cases[stage,Eastern Cooperative Oncology Group(ECOG),etc.],but more data are required in the literature.In this multi-center study,we focused on LS of advanced NSCLC with OS above 36 months to perform a clinical-pathological and molecular characterization.Methods:In the first step,we conducted a clinical-pathological characterization of the patients.Afterwards,we carried out a genetic analysis by comparing LS to a sample of short-term survivors(SS)(with an OS less than 9 months).We initially used whole-genome RNA-seq to identify differentiating profiles of LS and SS,and later confirmed these with reverse transcription-polymerase chain reaction(RT-PCR)for the rest of the samples.Results:A total of 94 patients were included,who were mainly men,former smokers,having adenocarcinoma(AC)-type NSCLC with an ECOG of 0-1.We obtained an initial differential transcriptome expression,displaying 5 over-and 33 under-expressed genes involved in different pathways:namely,the secretin receptor,surfactant protein,trefoil factor 1(T FF1),serpin,Ca-channels,and Tolllike receptor(TLRs)families.Finally,RT-PCR analysis of 40(20 LS/20 SS)samples confirmed that four genes(surfactant proteins and SFTP)were significantly down-regulated in SS compared to LS by using an analysis of covariance(ANCOVA)model:SFTPA1(P=0.023),SFTPA2(P=0.027),SFTPB{P=0.02),and SFT PC(P=0.047).Conclusions:We present a sequential genetic analysis of a sample of NSCLCLS with no driver alterations,obtaining a differential RNA-seq/RT-PCR profile showing an abnormal expression of SF genes.
机译:目的:没有驾驶员改变的非小细胞肺癌(NSCLC)的长期幸存者(LS),显示超过3年的整体存活(OS),包括约10%的化疗治疗的几种系列病例。是这些案例的经典预后因素[阶段,东方合作肿瘤组(ECOG)等。]但在文献中需要更多的数据。在这个多中心研究中,我们专注于LS的高级NSCLC与36个月以上的OS进行临床病理性和分子表征。方法:在第一步中,我们对患者进行了临床病理表征。在诉讼时,我们通过将LS与短期幸存者样本进行比较来进行遗传分析(SS)进行遗传分析(使用少于9个月的操作系统).WE最初使用全基因组RNA-SEQ以识别LS和SS的差异,并在其余的样品中具有逆转录 - 聚合酶链反应(RT-PCR)的倒数转录聚合酶链反应(RT-PCR)。 。结果:共有94名患者包括主要是男性,前吸烟者的ED,具有腺癌(AC) - 型NSCLC,ECOG为0-1.WE获得初始差异转录组表达,显示涉及不同途径的33个过度表达的基因:即,棘蛋白受体,表面活性剂蛋白质,三叶蛋白因子1(t ff1),蛇素,Ca-通道和达洛状受体(TLRS)家族。最后,RT-PCR分析40(20LS / 20s)样品证实了四种基因(表面活性剂蛋白和SFTP)通过使用协方差的分析(ANCOVA)模型(P = 0.023),SFTPA2(P = 0.027),SFTPB {P = 0.02),SFTPB {P = 0.02),SFTPB {P = 0.02),SFTPB(P = 0.02)和SFT在SS中显着下调PC(p = 0.047)。结论:我们介绍了没有驾驶员改变的Nsclcls样品的顺序遗传分析,获得了差分RNA-SEQ / RT-PCR分布,显示出SF基因的异常表达。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号